PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis

Leukemia

Volumn 31, Issue 6, 2017, Pages 1423-1433

  Carter, M J ^a   Cox, K L ^a   Blakemore, S J ^a   Turaj, A H ^a   Oldham, R J ^a   Dahal, L N ^a   Tannheimer, S ^b   Forconi, F ^a   Packham, G ^a   Cragg, M S ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; FOSTAMATINIB; GS 9820; IBRUTINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; RITUXIMAB; UNCLASSIFIED DRUG; VENETOCLAX; ANTINEOPLASTIC AGENT; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CD PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; METABOLISM; PATHOLOGY; SCID MOUSE; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-LIKE PROTEIN 11; CELL PROLIFERATION; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MICE; MICE, SCID; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 85006355875     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.333     Document Type: Article

References (57)

1. Burger J, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009; 114: 3367-3375.
2. Nore BF, Vargas L, Mohamed AJ, Branden LJ, Backesjo CM, Islam TC et al. Redistribution of Bruton's tyrosine kinase by activation of phosphatidylinositol 3-kinase and Rho-family GTPases. Eur J Immunol 2000; 30: 145-154.
3. Andjelkovic M, Alessi DR, Meier R, Fernandez A, Lamb NJC, Frech M et al. Role of translocation in the activation and function of protein kinase B. J Biol Chem 1997; 272: 31515-31524.
4. Vanhaesebroeck B, Whitehead MA, Pineiro R. Molecules in medicine mini-review: isoforms of PI3K in biology and disease. J Mol Med 2016; 94: 5-11.
5. Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110 alpha subunit of phosphoinositide 3-kinase. J Biol Chem 1999; 274: 10963-10968.
6. Bi L, Okabe I, Bernard DJ, Nussbaum RL. Early embryonic lethality in mice deficient in the p110 beta catalytic subunit of PI 3-kinase. Mamm Genome 2002; 13: 169-172.
7. Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E et al. Impaired B and T cell antigen receptor signaling in p110 delta PI 3-kinase mutant mice. Science 2002; 297: 1031-1034.
8. Bilancio A, Okkenhaug K, Camps M, Emery JL, Ruckle T, Rommel C et al. Key role of the p110 delta isoforrn of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110 delta function in B cells. Blood 2006; 107: 642-650.
9. Soond DR, Bjorgo E, Moltu K, Dale VQ, Patton DT, Torgersen KM et al. PI3K p110 delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. Blood 2010; 115: 2203-2213.
10. Ali K, Soond DR, Pineiro R, Hagemann T, Pearce W, Lim EL et al. Inactivation of PI (3)K p110 delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 2014; 510: 407.
11. Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014; 123: 3390-3397.
12. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370: 997-1007.
13. Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS et al. Resistance mechanisms for the bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014; 370: 2286-2294.
14. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ et al. The phosphoinositide 3 '-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011; 118: 3603-3612.
15. Herman SEM, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010; 116: 2078-2088.
16. Fiorcari S, Brown WS, McIntyre BW, Estrov Z, Maffei R, O'Brien S et al. The PI3-kinase delta inhibitor idelalisib (gs-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. Plos One 2013; 8: e83830.
17. Davids MS, Deng J, Wiestner A, Lannutti BJ, Wang L, Wu CJ et al. Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. Blood 2012; 120: 3501-3509.
18. Lannutti BJ, Meadows SA, Herman SEM, Kashishian A, Steiner B, Johnson AJ et al. CAL-101, a p110 delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011; 117: 591-594.
19. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014; 15: 49-63.
20. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002; 2: 183-192.
21. Llambi F, Moldoveanu T, Tait SWG, Bouchier-Hayes L, Temirov J, McCormick LL et al. A Unified Model of Mammalian BCL-2 Protein Family Interactions at the Mitochondria. Mol Cell 2011; 44: 517-531.
22. Enders A, Bouillet P, Puthalakath H, Xu YK, Tarlinton DM, Strasser A. Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim inhibits BCR stimulation-induced apoptosis and deletion of autoreactive B cells. J Exp Med 2003; 198: 1119-1126.
23. Bouillet P, Metcalf D, Huang DCS, Tarlinton DM, Kay TWH, Kontgen F et al. Proapoptotic Bcl-2 relative bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999; 286: 1735-1738.
24. Carter MJ, Cox KL, Blakemore SJ, Bogdanov YD, Happo L, Scott CL et al. BCR-signaling-induced cell death demonstrates dependency on multiple BH3-only proteins in a murine model of B-cell lymphoma. Cell Death Differ 2016; 23: 303-312.
25. Srinivasan L, Sasaki Y, Calado DP, Zhang B, Paik JH, DePinho RA et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 2009; 139: 573-586.
26. Woess C, Tuzlak S, Labi V, Drach M, Bertele D, Schneider P et al. Combined loss of the BH3-only proteins Bim and Bmf restores B-cell development and function in TACI-Ig transgenic mice. Cell Death Differ 2015; 22: 1477-1488.
27. Craxton A, Draves KE, Gruppi A, Clark EA. BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway. J Exp Med 2005; 202: 1363-1374.
28. Trushin SA, Carena AA, Bren GD, Rizza SA, Dong X, Abraham RS et al. SDF-1 alpha degrades whereas glycoprotein 120 upregulates Bcl-2 interacting mediator of death extralong isoform: implications for the development of T cell memory. J Immunol 2012; 189: 1835-1842.
29. Enzler T, Kater AP, Zhang W, Widhopf GF II, Chuang H-Y, Lee J et al. Chronic lymphocytic leukemia of E mu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression. Blood 2009; 114: 4469-4476.
30. Shugg RPP, Thomson A, Tanabe N, Kashishian A, Steiner BH, Puri KD et al. Effects of isoform-selective phosphatidylinositol 3-kinase inhibitors on osteoclasts actions on cytoskeletal organisation, survival, and resorption. J Biol Chem 2013; 288: 35346-35357.
31. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Doehner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
32. Lim SH, Vaughan AT, Ashton-Key M, Williams EL, Dixon SV, Chan HTC et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 2011; 118: 2530-2540.
33. Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 2002; 99: 6955-6960.
34. Bresin A, D'Abundo L, Narducci MG, Fiorenza MT, Croce CM, Negrini M et al. TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia. Cell Death Dis 2016; 7: e2071.
35. Johnson AJ, Lucas DM, Muthusamy N, Smith LL, Edwards RB, De lay MD et al. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood 2006; 108: 1334-1338.
36. DiLillo DJ, Weinberg JB, Yoshizaki A, Horikawa M, Bryant JM, Iwata Y et al. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia 2013; 27: 170-182.
37. Kater AP, Tonino SH, Kersten MJ, Hagenbeek A, Spiering M, van Oers MH et al. Interim analysis of dose-escalation stage of a phase 1b study evaluating safety and pharmacology of gs-9820, a second-generation, selective, pi3kd-inhibitor in recurrent lymphoid malignancies. Blood 2013; 122: 2881.
38. de Rooij MFM, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor-and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012; 119: 2590-2594.
39. Buchner M, Baer C, Prinz G, Dierks C, Burger M, Zenz T et al. Spleen tyrosine kinase inhibition prevents chemokine-and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood 2010; 115: 4497-4506.
40. Certo M, Moore VD, Nishino M, Wei G, Korsmeyer S, Armstrong SA et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006; 9: 351-365.
41. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7: 683-694.
42. Egle A, Harris AW, Bouillet P, Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA 2004; 101: 6164-6169.
43. Richter-Larrea JA, Robles EF, Fresquet V, Beltran E, Rullan AJ, Agirre X et al. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. Blood 2010; 116: 2531-2542.
44. Sinicrope FA, Rego RL, Okumura K, Foster NR, O'Connell MJ, Sargent DJ et al. Prognostic impact of Bim, Puma, and Noxa expression in human colon carcinomas. Clin Cancer Res 2008; 14: 5810-5818.
45. Beers SA, French RR, Chan CH, Lim SH, Jarrett TC, Mora Vidal R et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010; 115: 5191-5201.
46. Vogler M, Butterworth M, Majid A, Walewska RJ, Sun X-M, Dyer MJS et al. Concurrent up-regulation of BCL-X(L) and BCL2A1 induces approximately 1000fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009; 113: 4403-4413.
47. Paterson A, Mockridge CI, Adams JE, Krysov S, Potter KN, Duncombe AS et al. Mechanisms and clinical significance of BIM phosphorylation in chronic lym-phocytic leukemia. Blood 2012; 119: 1726-1736.
48. Pedersen IM, Kitada S, Leoni LM, Zapata JM, Karras JG, Tsukada N et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 2002; 100: 1795-1801.
49. Heinig K, Gaetjen M, Grau M, Stache V, Anagnostopoulos I, Gerlach K et al. Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia B-cell activation and proliferation. Cancer Discov 2014; 4: 1448-1465.
50. Szydlowski M, Kiliszek P, Sewastianik T, Jablonska E, Bialopiotrowicz E, Gorniak P et al. FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.Blood 2016; 127: 739-748.
51. Rahmani M, Anderson A, Habibi JR, Crabtree TR, Mayo M, Harada H et al. The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways. Blood 2009; 114: 4507-4516.
52. Young RM, Wu T, Schmitz R, Dawood M, Xiao W, Phelan JD et al. Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens. Proc Natl Acad Sci USA 2015; 112: 13447-13454.
53. Stadanlick JE, Kaileh M, Karnell FG, Scholz JL, Miller JP, Quinn WJ III et al. Tonic B cell antigen receptor signals supply an NF-kappa B substrate for prosurvival BLyS signaling. Nat Immunol 2008; 9: 1379-1387.
54. Gong Q, Ou QL, Ye SM, Lee WP, Cornelius J, Diehl L et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005; 174: 817-826.
55. Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis 2015; 6: e1593.
56. Seymour JF, Davids MS, Pagel JM, Kahl BS, Wierda WG, Puvvada S et al. ABT-199 (GDC-0199) in relapsed/refractory chronic lymphocytic leukemia and small lym-phocytic lymphoma: high response rates among patients with high risk disease features including unmated IgHV. Haematologica 2014; 99: 249-249.
57. Aguilar-Hernandez MM, Blunt MD, Dobson R, Yeomans A, Thirdborough S, Larrayoz M et al. IL-4 enhances expression and function of surface IgM in CLL cells. Blood 2016; 127: 3015-3025.